WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Saved in:
Bibliographic Details
Main Authors: Jonathan Barratt, Richard Lafayette, Hitoshi Suzuki, Sreelatha Melamadothil, Laura Kooeinga, Chula Herath, Muh Geot Wong, David Oldach, Asher Schachter, Mohit Mathur, Yusuke Suzuki
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924003474
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849468396816564224
author Jonathan Barratt
Richard Lafayette
Hitoshi Suzuki
Sreelatha Melamadothil
Laura Kooeinga
Chula Herath
Muh Geot Wong
David Oldach
Asher Schachter
Mohit Mathur
Yusuke Suzuki
author_facet Jonathan Barratt
Richard Lafayette
Hitoshi Suzuki
Sreelatha Melamadothil
Laura Kooeinga
Chula Herath
Muh Geot Wong
David Oldach
Asher Schachter
Mohit Mathur
Yusuke Suzuki
author_sort Jonathan Barratt
collection DOAJ
format Article
id doaj-art-b3a3d8487f7940399c99bae382eef8c1
institution Kabale University
issn 2468-0249
language English
publishDate 2024-04-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-b3a3d8487f7940399c99bae382eef8c12025-08-20T03:25:53ZengElsevierKidney International Reports2468-02492024-04-0194S125S12610.1016/j.ekir.2024.02.258WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIALJonathan Barratt0Richard Lafayette1Hitoshi Suzuki2Sreelatha Melamadothil3Laura Kooeinga4Chula Herath5Muh Geot Wong6David Oldach7Asher Schachter8Mohit Mathur9Yusuke Suzuki10Leicestershire, College of Life Sciences, United KingdomDepartment of Medicine, Stanford University, StanfordDepartment of Nephrology, Juntendo University Urayasu Hospital, ChibaDepartment of Nephrology, Government Medical College, Kozhikode, KeralaResearch Division, Colorado Kidney Care, DenverDepartment of Nephrology Unit, Sri Jayewardenepura General Hospital, NugegodaRenal Research, Concord Repatriation General Hospital, ConcordNephrology Clinical Development, Visterra, Inc, BostonNephrology Clinical Development, Visterra, Inc, BostonNephrology Clinical Development, Visterra, Inc, BostonDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo,http://www.sciencedirect.com/science/article/pii/S2468024924003474
spellingShingle Jonathan Barratt
Richard Lafayette
Hitoshi Suzuki
Sreelatha Melamadothil
Laura Kooeinga
Chula Herath
Muh Geot Wong
David Oldach
Asher Schachter
Mohit Mathur
Yusuke Suzuki
WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
Kidney International Reports
title WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
title_full WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
title_fullStr WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
title_full_unstemmed WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
title_short WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
title_sort wcn24 1799 hematuria resolution with the april blocking monoclonal antibody sibeprenlimab in patients with iga nephropathy in a phase 2 randomized controlled trial
url http://www.sciencedirect.com/science/article/pii/S2468024924003474
work_keys_str_mv AT jonathanbarratt wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT richardlafayette wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT hitoshisuzuki wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT sreelathamelamadothil wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT laurakooeinga wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT chulaherath wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT muhgeotwong wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT davidoldach wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT asherschachter wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT mohitmathur wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial
AT yusukesuzuki wcn241799hematuriaresolutionwiththeaprilblockingmonoclonalantibodysibeprenlimabinpatientswithiganephropathyinaphase2randomizedcontrolledtrial